Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Borg

Showing results (211-220 of 224) with videos related to

Pageof 23
Sort By:
Cancer Research|May 20, 2016
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell ImmunityLaurent Beziaud, Laura Mansi, Patrice Ravel, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 5, 2025
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)Thierry Lecomte, Bruno Giraudeau, Jean-Marc Phelip, et al.
The Journal of Clinical Investigation|August 3, 2004
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effectsChristophe Borg, Magali Terme, Julien Taïeb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2022
Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation StudyOlivier Adotévi, Dewi Vernerey, Pascale Jacoulet, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2022
Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID)Mathias Brugel, Léa Letrillart, Camille Evrard, et al.
Biomedicines|July 2, 2021
The NHance<sup>®</sup> Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer PatientsPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Therapeutic Advances in Medical Oncology|December 17, 2020
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinomaStefano Kim, Aurélia Meurisse, Laurie Spehner, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 18, 2024
Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trialDamien Botsen, Sylvie Chabaud, Hervé Perrier, et al.
Cancer|November 2, 2021
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphomaNicolas Leupin, Pier Luigi Zinzani, Franck Morschhauser, et al.
BMC Cancer|August 27, 2017
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)Stefano Kim, Marine Jary, Thierry André, et al.
Pageof 23

Showing results (211-220 of 224) with videos related to

Sort By:
Pageof 23
Cancer Research|May 20, 2016
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell ImmunityLaurent Beziaud, Laura Mansi, Patrice Ravel, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 5, 2025
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)Thierry Lecomte, Bruno Giraudeau, Jean-Marc Phelip, et al.
The Journal of Clinical Investigation|August 3, 2004
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effectsChristophe Borg, Magali Terme, Julien Taïeb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2022
Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation StudyOlivier Adotévi, Dewi Vernerey, Pascale Jacoulet, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2022
Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID)Mathias Brugel, Léa Letrillart, Camille Evrard, et al.
Biomedicines|July 2, 2021
The NHance<sup>®</sup> Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer PatientsPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Therapeutic Advances in Medical Oncology|December 17, 2020
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinomaStefano Kim, Aurélia Meurisse, Laurie Spehner, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 18, 2024
Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trialDamien Botsen, Sylvie Chabaud, Hervé Perrier, et al.
Cancer|November 2, 2021
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphomaNicolas Leupin, Pier Luigi Zinzani, Franck Morschhauser, et al.
BMC Cancer|August 27, 2017
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)Stefano Kim, Marine Jary, Thierry André, et al.
Pageof 23